Israeli chatbot could diagnose early Alzheimer’s disease
Hundreds of drugs have been developed to address Alzheimer’s disease, says Dr. Shahar Arzy, director of the computational neuropsychiatry lab at Hadassah Hebrew University Medical Center in Jerusalem. “Do you know how many have been found effective? Zero.”
But if patients could be diagnosed in the preclinical stages of the disease, perhaps some of the new biological medications showing excellent results in other domains of neurology could be effective when applied early enough in the course of Alzheimer’s disease.
